Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
2.
Diabetes Care ; 39(2): 179-86, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26798148

ABSTRACT

The current classification system presents challenges to the diagnosis and treatment of patients with diabetes mellitus (DM), in part due to its conflicting and confounding definitions of type 1 DM, type 2 DM, and latent autoimmune diabetes of adults (LADA). The current schema also lacks a foundation that readily incorporates advances in our understanding of the disease and its treatment. For appropriate and coherent therapy, we propose an alternate classification system. The ß-cell-centric classification of DM is a new approach that obviates the inherent and unintended confusions of the current system. The ß-cell-centric model presupposes that all DM originates from a final common denominator-the abnormal pancreatic ß-cell. It recognizes that interactions between genetically predisposed ß-cells with a number of factors, including insulin resistance (IR), susceptibility to environmental influences, and immune dysregulation/inflammation, lead to the range of hyperglycemic phenotypes within the spectrum of DM. Individually or in concert, and often self-perpetuating, these factors contribute to ß-cell stress, dysfunction, or loss through at least 11 distinct pathways. Available, yet underutilized, treatments provide rational choices for personalized therapies that target the individual mediating pathways of hyperglycemia at work in any given patient, without the risk of drug-related hypoglycemia or weight gain or imposing further burden on the ß-cells. This article issues an urgent call for the review of the current DM classification system toward the consensus on a new, more useful system.


Subject(s)
Diabetes Mellitus, Type 1/classification , Diabetes Mellitus, Type 2/classification , Insulin-Secreting Cells/pathology , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Humans , Hyperglycemia/drug therapy , Hypoglycemic Agents/therapeutic use , Insulin Resistance
SELECTION OF CITATIONS
SEARCH DETAIL